Orchid Pharma (BOM:524372) Cyclically Adjusted PS Ratio: (As of Sep. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524372 Orchid Pharma Ltd BOM:524372
65 GF Score
Price ₹1,081.45
GF Value ₹977.08
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Orchid Pharma Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Orchid Pharma  (BOM:524372) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Orchid Pharma Cyclically Adjusted PS Ratio Related Terms


Orchid Pharma Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Orchid Pharma's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orchid Pharma Cyclically Adjusted PS Ratio Chart

Orchid Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 7.46 5.66 3.34

Orchid Pharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.13 4.95 5.34 3.34 6.68

BOM:524372 vs ZTS: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Orchid Pharma Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Orchid Pharma's Cyclically Adjusted PS Ratio falls into.


BOM:524372
65GF Score
Orchid Pharma Ltd BOM:524372
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Orchid Pharma Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Orchid Pharma's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Orchid Pharma's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=59.972/167.3573*167.3573
=59.972

Current CPI (Jun. 2026) = 167.3573.

Orchid Pharma Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
200809 48.952 55.850 146.688
200812 46.765 56.232 139.181
200903 39.596 56.615 117.049
201003 65.030 0.000
201103 70.768 0.000
201203 76.889 0.000
201309 91.042 0.000
201503 0.000 97.163 0.000
201603 0.000 102.518 0.000
201703 0.000 105.196 0.000
201803 0.000 109.786 0.000
201906 15.222 120.880 21.075
201909 14.796 123.175 20.103
201912 14.552 126.235 19.292
202003 27.321 124.705 36.665
202006 29.195 127.000 38.472
202009 26.595 130.118 34.206
202012 25.182 130.889 32.198
202103 29.292 131.771 37.203
202106 22.617 134.084 28.229
202109 31.295 135.847 38.554
202112 39.537 138.161 47.892
202203 43.642 138.822 52.613
202206 32.092 142.347 37.730
202209 40.486 144.661 46.838
202212 39.141 145.763 44.940
202303 51.426 146.865 58.602
202306 36.065 150.280 40.163
202309 39.187 151.492 43.291
202312 43.493 152.924 47.598
202403 42.805 153.035 46.811
202406 48.188 155.789 51.766
202409 43.908 157.882 46.543
202412 42.852 158.323 45.297
202503 46.822 157.552 49.736
202506 51.891 159.755 54.360
202509 38.156 162.289 39.348
202512 40.866 163.281 41.886
202603 46.848 164.272 47.728
202606 59.972 167.357 59.972

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Orchid Pharma (BOM:524372) Overvalued in 2026?

Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued. The current stock price of ₹1,081.45 is trading 10.7% above its estimated GF Value™ of ₹977.08. GuruFocus considers Orchid Pharma to be Fairly Valued.

Key valuation signals for BOM:524372:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: ₹977.08 vs. price of ₹1,081.45 (10.7% above fair value)
  • GF Score™: 65/100 with 8 warning signs

No single metric tells the full story. See the BOM:524372 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Orchid Pharma Business Description

Other Exchanges ORCHPHARMA:India
Address Sector 74A, 15th Floor, Tower-1, DLF Corporate Greens, Narsinghpur, Gurugram, HR, IND, 122004
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
65GF Score

Get the complete analysis for BOM:524372

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,081.45
Price
₹977.08
GF Value